IP Library Granted Patent US 12,636,445
Granted Patent B2
US 12,636,445 · App. 18/368,910 · Granted May 26, 2026

System and method for delivery of gas to a tissue

Inventors: Hila Confino (Rehovot, IL); Steven A. Lisi (Garden City, NY); Rinat Kalaora (Rehovot, IL); Amir Avniel (Rehovot, IL); Matan Goldshtein (Rehovot, IL); Shay Yarkoni (Rehovot, IL)
Assignee: Beyond Air, Inc.
A61M13/003A61K9/0019A61K33/00A61K39/0011A61K40/24A61M39/223A61P35/00A61M2202/0275A61M2205/3334A61M2205/3344A61M2205/7536
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,445
App. No.
18/368,910
Granted
May 26, 2026
Kind
B2
Abstract

A system for delivery of gas to a tissue, comprises: a first container containing the gas, an applicator having a distal end arranged to deliver the gas to the tissue, a second container containing a purging gas; and a flow control system for controlling flow of gas. The system also comprises a three-port valve having a first port for receiving the gas from the first container, a second port for receiving the purging gas from the second container, and a third port in fluid communication with the applicator. The valve is switchable between a first state at which the first port fluidly connects to the third port, and a second state at which the second port fluidly connects to the third port.

Claims (30)

1 . A system for delivery of gas to a tissue, the system comprising:

a container containing the gas, wherein the gas is gaseous nitric oxide (gNO);

an applicator, wherein the applicator is configured to deliver the gas to the tissue;

a three-port valve having a first port for receiving the gas from the container, a second port for receiving a purging gas or connecting to a vacuum source, and a third port in fluid communication with the applicator, the three-port valve being switchable between a first state at which the first port fluidly connects to the third port, and a second state at which the second port fluidly connects to the third port;

a flow control system for controlling flow of gas exiting the three-port valve;

a computerized controller for automatically controlling the flow control system, according to at least one of: a predetermined gas flow rate, a predetermined total amount of the gas flowing through the flow control system, and a predetermined total amount of time in which the gas flows through the flow control system; and

an adjustable pressure regulator, in fluid communication with the third port of the three-port valve, and being configured for maintaining a pressure which is below a predetermined threshold when the three-port valve assumes the first state, and a pressure which is above the predetermined threshold when the three-port valve assumes the second state;

wherein a concentration of the gNO in the container is from about 1,000 ppm to about 1,000,000 ppm.

2 . The system according to claim 1 , wherein the tissue is a tumor, and the applicator is configured to deliver the gas intratumorally.

3 . The system according to claim 1 , further comprising a filter, wherein the filter is configured to remove at least one of gNO and nitrogen dioxide (NO 2 ) from excess gas exiting the applicator.

4 . The system according to claim 1 , further comprising a suctioning device, wherein the suctioning device is configured to withdraw excess gas exiting the applicator.

5 . The system according to claim 1 , wherein the flow control system comprises a flow controller and a flow limiter.

6 . The system according to claim 5 , wherein the flow limiter is configured to control a flow rate of the gas before the gas enters the flow controller.

7 . The system according to claim 1 , wherein the flow control system comprises an orifice and a second valve, wherein the second valve is configured to control the orifice.

8 . The system according to claim 7 , wherein the second valve is a solenoid valve.

9 . The system according to claim 1 , wherein the predetermined total amount of the gas is one of a volume or a mass.

10 . The system according to claim 1 , wherein the applicator and the container are disposable.

11 . The system according to claim 1 , wherein the container has a volume of less than 100 cc.

12 . The system according to claim 1 , wherein a gas pressure in the container is less than 10 bar.

13 . The system according to claim 1 , further comprising an arrangement of sensors configured to (i) be distributed in a treatment room, (ii) sense the gas, and (iii) issue an alert signal when a level of the gas is above a respective predetermined threshold.

14 . The system according to claim 1 , wherein the computerized controller is configured to control the three-port valve.

15 . A method for delivery of gas to a tissue, the method comprising:

providing a system according to claim 1 and in the system:

connecting the container to the three-port valve;

switching the three-port valve to the first state, thereby delivering the gas to the tissue; and

disconnecting the applicator and the container.

16 . The method according to claim 15 , wherein the tissue is a tissue of a subject, and the method further comprising delivering air or oxygen or oxygen-enriched air to the subject.

17 . The method according to claim 16 , wherein the delivering is by a mask.

18 . The method according to claim 16 , wherein the subject is a mammal.

19 . The method according to claim 16 , wherein the subject is a human.

Assignments (1)
SECURITY INTEREST Recorded Nov 6, 2025
From: BEYOND AIR, INC.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 072815/0119 →
Continuity (10)
Continuation 17980364 · Nov 3, 2022
Continuation 17620696
Provisional Application 63090345 · Oct 12, 2020
Provisional Application 63027120 · May 19, 2020
Provisional Application 62985611 · Mar 5, 2020
Provisional Application 62984926 · Mar 4, 2020
Provisional Application 62982817 · Feb 28, 2020
Provisional Application 62963849 · Jan 21, 2020
Provisional Application 62939975 · Nov 25, 2019
Related Publication 20240075220A1 · Mar 7, 2024
References Cited (63)
US 5345928A · Lindkvist · 1994 [cited by applicant]
US 5873359A · Zapol et al. · 1999 [cited by applicant]
US 6962154B2 · Krebs · 2005 [cited by examiner]
US 7955294B2 · Miller et al. · 2011 [cited by applicant]
US 8017582B2 · Shirwan et al. · 2011 [cited by applicant]
US 8168232B2 · Graham et al. · 2012 [cited by applicant]
US 20020078958A1 · Stenzler · 2002 [cited by applicant]
US 20020155164A1 · Figley et al. · 2002 [cited by applicant]
US 20040258772A1 · Otterbein et al. · 2004 [cited by applicant]
US 20050004511A1 · Figley et al. · 2005 [cited by applicant]
US 20050217679A1 · Miller · 2005 [cited by examiner]
US 20060290525A1 · Andersen · 2006 [cited by examiner]
US 20070275100A1 · Miller · 2007 [cited by applicant]
US 20080193566A1 · Miller et al. · 2008 [cited by applicant]
US 20090205655A1 · Montgomery · 2009 [cited by examiner]
US 20130239962A1 · Goldstein · 2013 [cited by applicant]
US 20150320951A1 · Acker · 2015 [cited by examiner]
US 20170043115A1 · Murphy · 2017 [cited by examiner]
US 20180280654A1 · Borrello · 2018 [cited by applicant]
US 20220111173A1 · Lautner · 2022 [cited by examiner]
DE 10306766A1 · 2004 [cited by applicant]
WO 2005110441A2 · 2005 [cited by applicant]
WO 2008095311A1 · 2008 [cited by applicant]
WO 2008095312A1 · 2008 [cited by applicant]
WO 2009023750A1 · 2009 [cited by applicant]
WO 2013132500A1 · 2013 [cited by applicant]
WO 2013132503A1 · 2013 [cited by applicant]
WO 2014008490A1 · 2014 [cited by applicant]
WO 2016077635A1 · 2016 [cited by applicant]
WO 2016168680A1 · 2016 [cited by applicant]
WO 2017055995A1 · 2017 [cited by applicant]
WO 2019130117A1 · 2019 [cited by applicant]
WO 2021105900A1 · 2021 [cited by applicant]
WO 2021105901A2 · 2021 [cited by applicant]
WO 2022043931A2 · 2022 [cited by applicant]
WO 2022249104A1 · 2022 [cited by applicant]
International Preliminary Report on Patentability dated Jun. 9, 2022 from the International Bureau of WIPO Re. Application No. PCT/IB2020/061149. (8 pages). [cited by applicant]
International Preliminary Report on Patentability dated Jun. 9, 2022 from the International Bureau of WIPO Re. Application No. PCT/IB2020/061150. (15 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Jul. 9, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/061150. [cited by applicant]
International Search Report and the Written Opinion Dated May 12, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/061149. [cited by applicant]
Invitation to Pay Additional Fees Dated May 3, 2021 From the International Searching Authority Re. Application No. PCT/TB2020/061150. (2 Pages). [cited by applicant]
Official Action Dated Jun. 17, 2022 from US Patent and Trademark Office Re. U.S. Appl. No. 17/620/696. (13 pages). [cited by applicant]
Bonavida , et al., “Nitric Oxide-Mediated Sensitization of Resistant Tumor Cells lo Apoptosis by Chemo-Immunotherapeutics”, Redox Biology, 6, Aug. 18. 2015, 486-494. [cited by applicant]
Confino , et al., “Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)”, Globe News Wire, Aug. 27, 2020, 7 pgs. [cited by applicant]
Confino , et al., “Gaseous Nitric Oxide at High Concentrations Is a Powerful Anti-Tumor Agent Both in-Vitro and in-Vivo”, AACR, Poster, Jun. 2020. [cited by applicant]
Confino , et al., “Nitric Oxide Tumor Ablation Stimulates an Anti-Tumor Immune Response in Mice”, AACR, American Association for Cancer Research, AACR Virtual Special Conference on Tumor Immunology and Immunotherapy, Is… [cited by applicant]
Confino, H. , et al., “Nitric Oxide Lung Cancer Active Vaccination”, 2020 North America Conference on Lung Cancer, #NACLC20, Worldwide Virtual Event, Oct. 16-17, 2020, Slide Show, 14 pgs. [cited by applicant]
El-Naa , et al., “Sildenafil Potentiates the Antitumor Activity of Cisplatin by Induction of Apoptosis and Inhibition of Proliferation and Angiogenesis”, Drug Design, Development and Therapy, 10, Nov. 16, 2016, 3661-367… [cited by applicant]
Huerta , “Nitric Oxide for Cancer Therapy”, Future Science, 1(1), Aug. 1, 2015, FSO44-I-FSO44-9. [cited by applicant]
Keisari , et al., “Activation of Local and Systemic Anti-Tumor Immune Responses by Ablation of Solid Tumors With Intratumoral Electrochemical or Alpha Radiation Treatments”, Cancer Immunology, Immunotherapy, 63(1), Aug.… [cited by applicant]
Knavel , et al., “Tumor Ablation: Common Modalities and General Practices”, Techniques in Vascular and Interventional Radiology, 16(4), Dec. 2013, 192-200. [cited by applicant]
Lin , et al., “Non-Thermal Plasma as A Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells”, Advanced Science, 6(6), Jan. 28, 2019, 1802062-1-1802062-1… [cited by applicant]
Nath , et al., “Nitric Oxide-Releasing Aspirin Suppresses NF-KB Signaling in Estrogen Receptor Negative Breast Cancer Cells In Vitro and In Vivo”, Molecules, 20(7), Jul. 9, 2015, 12481-12499. [cited by applicant]
Ning , et al., “Novel Nitric Oxide Generating Compound Glycidyl Nitrate Enhances the Therapeutic Efficacy of Chemotherapy and Radiotherapy”, Biochemical and Biophysical Research Communications, 447(3), Apr. 13, 2014, 53… [cited by applicant]
Rizi , et al., “Nitric Oxide: The Forgotten Child of Tumor Metabolism”, Trends in Cancer, 3(9), Aug. 18, 2017, 659-672. [cited by applicant]
Schairer, D. O, et al., “The potential of nitric oxide releasing therapies as antimicrobial agents”, Virulence, 3(3)DOI: 10.4161/viru.20328, May 1, 2012, 271-279. [cited by applicant]
Seabra , et al., “Nitric Oxide Donors for Prostate and Bladder Cancers: Current State and Challenges”, European Journal of Pharmacology, 826, Mar. 1, 2018, 158-168. [cited by applicant]
Slovak , et al., “Immuno-Thermal Ablations—Boosting the Anticancer Immune Response”, Journal for Immuno Therapy of Cancer, 5(1), Oct. 17, 2017, 78-1-78-15. [cited by applicant]
Srivatsan , et al., “Allogeneic Tumor Cell Vaccines. The Promise and Limitations in Clinical Trials”, Human Vaccines & Immunotherapeutics, 10(1), Sep. 24, 2013, 52-63. [cited by applicant]
Vannini , et al., “The Dual Role ofiNOS in Cancer”, Redox Biology, 6, Aug. 24, 2015, 334-343. [cited by applicant]
Weyerbrock , et al., “Growth Inhibition and Chemosensitization of Exogenous Nitric Oxide Released From NONOates in Glioma Cells In Vitro: Laboratory Investigation”, Journal of Neurosurgery, 110(1), Jan. 2009, 128-136. [cited by applicant]
Olson, S. Y, et al., “Abstract 5631: Nitric oxide-based immune response modifications: A novel paradigm in tumor vaccine development against melanoma”, Can. Res., 51(8), Suppl., Apr. 1, 2010, 1 pg. [cited by applicant]
Wang, C., “Nitric Oxide Delivery System for Cell Culture Studies”, Annals of Biomed Eng, 31, 2003, 65-79. [cited by applicant]